title: Highlights from the ASCO annual meeting.
authors.forename: Carrie
authors.initials: C
authors.lastname: Printz
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000600:supply & distribution* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D016543:Central Nervous System Neoplasms / Q000188:drug therapy; D011307:Drug Prescriptions; D005909:Glioblastoma / Q000188:drug therapy; D015276:Health Care Rationing; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy*; D000077594:Nivolumab; D010818:Practice Patterns, Physicians'; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology; D012955:Societies, Medical; D016896:Treatment Outcome; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000074324:Ipilimumab; D000068258:Bevacizumab; D000077594:Nivolumab